(Buspirone hydrochloride + testosterone) is under clinical development by Freya Pharma Solutions and currently in Phase II for Female Hypoactive Sexual Desire Disorder. According to GlobalData, Phase II drugs for Female Hypoactive Sexual Desire Disorder have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Buspirone hydrochloride + testosterone)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Buspirone hydrochloride + testosterone) overview

Buspirone hydrochloride in combination with testosterone (Lybridos) is under development for the treatment of HSDD (hypoactive sexual desire disorder) in females as a result of inhibitory mechanisms in the brain. It is administered through oral and sublingual routes. Lybridos is a fixed-combination tablet with an inner-core component of buspirone coated with a polymeric time-delay coating and an outer polymeric coating containing testosterone with hydroxypropyl-beta cyclodextrin. Buspirone targets 5-HT1A and dopamine D2 and testosterone targets androgen receptor.

Freya Pharma Solutions overview

Freya Pharma Solutions (Freya) is a biotech business focused on the discovery of effective pharmacological therapeutics for female sexual interest/arousal problem in late-stage clinical trials (FSIAD). Freya is headquartered in Amsterdam, North Holland, The Netherlands.

For a complete picture of (Buspirone hydrochloride + testosterone)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.